Dr. O'shaughnessy

Dr. Joyce O’Shaughnessy on Promising Agents in Triple-Negative Breast Cancer

Dr. O’Shaughnessy on Differentiating Between CDK 4/6 Inhibitors

Dr. O'Shaughnessy on Avastin as Her Standard of Care

Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast Cancer

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast Cancer

Dr. O'Shaughnessy Describes the School of Breast Oncology

Dr. O'Shaughnessy on Continued Access to Avastin

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

Dr. O'Shaughnessy on the Future of TNBC Treatment

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

Dr. O’Shaughnessy on Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast Cancer

Targeted Oncology

Dr. O'Shaughnessy on the Future of Breast Cancer Treatment

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer

Dr. O'Shaughnessy Discusses Negative TNBC Iniparib Trial Results

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC Treatment

Insights from Dr. O’Shaughnessy: Board-Certified Plastic Surgeon

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases

Dr. O'Shaughnessy on the Future of Breast Cancer Biomarkers

Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer

Geographies of Abortion (Chaired by Dr. Aideen O'Shaughnessy)

Reproductive Justice Research Network